Overview
Nirmala (“Nimmi”) Ramanujam is the Robert W. Carr Professor of Biomedical Engineering and Professor of Cancer Pharmacology, Cancer Biology, and Global Health and founder of the Center for Global Women’s Health Technologies (GWHT) at Duke University. Her work addresses access gaps across the cancer care continuum both locally and globally. Her group develops low-cost imaging, artificial intelligence, and digital health platforms to decentralize the early detection of cervical cancer, and immune-based injectables and metabolic biomarkers for breast cancer treatment. Across both programs, she addresses access in different ways—expanding prevention where healthcare infrastructure is limited and improving access to treatment where therapies are available, yet lengthy and prohibitively expensive. She founded Calla Health to translate women’s health technologies into practice and co-developed The (In)visible Organ, a documentary that raises awareness and addresses stigma as barriers to care. She also leads experiential STEM initiatives that train students in systems-based, equity-centered technology development and she has authored a textbook, Biomedical Engineering and Global Health. She is a Fellow of the National Academy of Engineeringand theNational Academy of Inventors, a Fulbright Scholar, and recipient of a number of awards, notably of theDepartment of Defense Breast Cancer Innovator Award, theIEEE Biomedical Engineering Technical Field Award and the Anita B social impact award.
Current Appointments & Affiliations
Recent Publications
Mechanistic model of phase-transitioning therapeutics injected into poroelastic tissue for improved targeting of superficial tumors.
Journal Article Scientific reports · February 2026 Full text CiteOptimization of injections with speculum-compatible devices to deliver ethyl cellulose-ethanol into the cervix to treat cervical dysplasia.
Journal Article Scientific reports · December 2025 Intracervical injections directly deliver therapies into the cervix. We previously explored ethyl cellulose (EC)-ethanol intracervical injections as a treatment for cervical dysplasia in low- and middle-income countries. Here we: (1) compared swine and hum ... Full text CiteUsability of Speculum-Compatible Injection Devices for Administering Ethyl Cellulose-Ethanol Ablation to Treat Cervical Neoplasia in Low- and Middle-Income Countries.
Journal Article Annals of biomedical engineering · October 2025 PurposeCurrent treatments for cervical neoplasia are often inaccessible in low- and middle-income countries (LMICs), which contributes to high cervical cancer mortality. We previously developed a low-cost ablative therapy using ethanol mixed with ... Full text CiteRecent Grants
Duke Research Training Program in Surgical Oncology
Inst. Training Prgm or CMEMentor · Awarded by National Cancer Institute · 2024 - 2029A single shot therapy will accelerate the elimination of breast cancer
ResearchPrincipal Investigator · Awarded by United States Army Medical Research Acquisition Activity · 2024 - 2028The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program
ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028View All Grants